1. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
- Author
-
DeWilde, Kaitlin E., Levitch, Cara F., Murrough, James W., Mathew, Sanjay J., and Iosifescu, Dan V.
- Subjects
- *
THERAPEUTICS , *MENTAL depression , *KETAMINE , *TREATMENT effectiveness , *ANTIDEPRESSANTS , *METHYL aspartate receptors , *PUBLIC health , *CLINICAL trials - Abstract
Major depressive disorder (MDD) is one of the most disabling diseases worldwide and is becoming a significant public health threat. Current treatments forMDDprimarily consist of monoamine-targeting agents and have limited efficacy. However, the glutamate neurotransmitter system has recently come into focus as a promising alternative for novel antidepressant treatments. We review the current data on the glutamate NMDA receptor antagonist ketamine, which has been shown in clinical trials to act as a rapid antidepressant inMDD.We also examine ketamine efficacy on dimensions of psychopathology, including anhedonia, cognition, and suicidality, consistent with theNIMH Research Domain Criteria initiative. Other aspects of ketamine reviewed in this paper include safety and efficacy, different administration methods, and the risks of misuse of ketamine outside of medical settings. Finally, we conclude with a discussion of glutamatergic agents other than ketamine currently being tested as novel antidepressants. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF